Codiak BioSciences (CDAK)

Wednesday

9:34 PM

ThesisRecent clinical trial delays and high operating losses have led to increased skepticism among investors regarding Codiak's ability to execute on its growth strategy.

Revenue Outlook

Metric	FY2020	FY2021
Revenue	$3M	$23M
Rev. Growth	+651%	+687%
EPS	$-5.11	$-1.91
EPS Growth	+15.3%	+62.6%
P/E	—	—

What Moves the Stock

01Clinical trial results for lead candidates, particularly in oncology
02Partnership announcements with major pharmaceutical companies
03Regulatory approvals or setbacks for exosome therapies
04Market adoption rates of exosome-based treatments
05Therapeutic development partnerships - 100%
06Growth in targeted therapies within oncology
07Increased investment in innovative drug delivery systems

FY2021 Snapshot

Revenue: $23M
Rev. Growth: +687%
Gross Margin: 100%
Op. Margin: -303%
Net Margin: -182%
Net Income: $-42M
NI Growth: +53.2%
EPS: $-1.91

CDAK Chart

No chart data

My Notes

"Investors are increasingly cautious as the path to commercialization appears more challenging than previously anticipated."
Moat: Codiak's proprietary engEx Platform provides a significant technological edge…
growth - Investors looking for high-risk, high-reward opportunities in innovative biotech solutions.
Higher interest rates could increase the cost of capital for Codiak, impacting its ability to fund R&D initiatives and potentially slowing…
Watch on earnings: Clinical trial enrollment rates, Partnership revenue growth, R&D expenditure as a percentage of revenue.

One Sentence Summary:

Codiak BioSciences: the story is balanced — clinical trial results for lead candidates, particularly in oncology.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers